Celularity- Warrants (16/07/2026) Debt to Equity

Celularity- Warrants (16/07/2026) (CELUW) currently reports a debt-to-equity ratio of -1.93. That is below the Healthcare sector average of 0.31. Use the charts on this page to explore Celularity- Warrants (16/07/2026)'s debt-to-equity ratio history and peer comparisons.

Celularity- Warrants (16/07/2026)'s debt-to-equity ratio of -1.93 is lower than the Healthcare sector average of 0.31. That is roughly 725.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Celularity- Warrants (16/07/2026)'s market price to a fundamental measure such as earnings, sales, or book value. At -1.93, CELUW can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -1.93, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.31. From there, open related valuation or income-statement pages for Celularity- Warrants (16/07/2026), and consider following CELUW for alerts when major investors trade the stock.

Celularity- Warrants (16/07/2026) is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -1.93 versus a sector average near 0.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CELUW with unrelated industries.